|1.||Hammershaimb, L: 3 articles (01/2002 - 01/2002)|
|2.||Blessing, John A: 2 articles (05/2002 - 01/2002)|
|3.||Zhang, J: 2 articles (01/2002 - 01/2002)|
|4.||Blanke, C D: 2 articles (01/2002 - 01/2002)|
|5.||Punt, C J A: 2 articles (01/2002 - 01/2002)|
|6.||Lochs, H: 2 articles (01/2002 - 05/2000)|
|7.||Austin, Christopher P: 1 article (07/2013)|
|8.||Lee, Dae-Hee: 1 article (07/2013)|
|9.||Alcorta, David: 1 article (07/2013)|
|10.||Sakamuru, Srilatha: 1 article (07/2013)|
|1.||Pneumocystis Pneumonia (Pneumocystis carinii Pneumonia)
11/01/1988 - "Efficacy of trimetrexate, a potent lipid-soluble antifolate, in the treatment of rodent Pneumocystis carinii pneumonia."
01/01/1990 - "This combination should be selected for studies to compare trimetrexate with other therapies for pneumocystis pneumonia."
03/01/1994 - "FDA approves trimetrexate as second-line therapy for Pneumocystis carinii pneumonia."
02/01/1992 - "The primary objective of this article is to introduce readers to the use of a new agent, trimetrexate (TMTX), in the treatment of Pneumocystis carinii pneumonia (PCP). "
01/27/1989 - "Trimetrexate for Pneumocystis carinii pneumonia."
|2.||Acquired Immunodeficiency Syndrome (AIDS)
03/01/1988 - "It appears that the oral route is a practical route of administration for trimetrexate in patients with acquired immunodeficiency syndrome requiring long-term outpatient treatment or prophylaxis for P. "
03/01/1988 - "The pharmacokinetic behavior of trimetrexate administered either by intravenous bolus or orally was studied in six patients with acquired immunodeficiency syndrome with a reversed-phase high-pressure liquid chromatography assay. "
03/01/1988 - "Bioavailability of oral trimetrexate in patients with acquired immunodeficiency syndrome."
08/01/2005 - "The lipophilic antifolate trimetrexate (TMQ), which is an FDA-approved drug for the treatment of Pneumocystis carinii infection in AIDS patients, is a potent inhibitor of T. "
06/01/1993 - "Trimetrexate alone had dramatic but transient activity in sulfonamide-intolerant patients and thus is not adequate as single-agent therapy for AIDS-associated toxoplasmosis."
05/01/2002 - "This is a Phase II group-wide study of the Gynecologic Oncology Group to determine the toxicity and objective response rate of trimetrexate (TMTX) in patients with advanced, persistent, or recurrent mixed mesodermal tumors of the uterus who have failed higher priority treatment protocols. "
05/01/2002 - "Phase II evaluation of oral trimetrexate in mixed mesodermal tumors of the uterus: a gynecologic oncology group study."
01/01/1993 - "Trimetrexate (TMTX), a lipophilic antifol, was evaluated in a Pediatric Oncology Group (POG) Phase I trial in children with refractory solid tumors. "
01/01/1993 - "Phase I trial of trimetrexate in pediatric solid tumors: a Pediatric Oncology Group study."
06/15/1987 - "Trimetrexate, a new antifolate compound, was administered by 30-min infusions weekly for 3 weeks to 29 patients with solid tumors in a Phase I study. "
|4.||Colorectal Neoplasms (Colorectal Cancer)
10/01/1997 - "However, recent trials have raised the possibility that the combination of trimetrexate (TMTX) plus 5-FU/LV may improve response rates and survival in patients with metastatic colorectal cancer. "
01/01/1990 - "A phase II study of trimetrexate therapy for metastatic colorectal carcinoma."
10/01/1997 - "Trimetrexate: review and current clinical experience in advanced colorectal cancer."
01/01/1990 - "Our data suggest that trimetrexate given at these doses and in this schedule is not active against colorectal carcinoma."
10/01/2005 - "A phase I/II study of trimetrexate and capecitabine in patients with advanced refractory colorectal cancer."
01/01/1995 - "A phase II study of continuous infusion of trimetrexate in patients with refractory acute leukemia."
04/01/1993 - "A phase I trial of trimetrexate (NSC352122) on a daily x 5 schedule in patients with refractory adult leukemia."
01/01/1997 - "The synergistic effect of trimetrexate (TMTX) and sulphonamide derivatives of quinazoline on the cultured 5178Y murine leukemia cells was examined. "
01/01/1995 - "Six patients with refractory or relapsed acute leukemia were treated with a 5-day continuous infusion of trimetrexate of 8 mg/m2/day after an initial loading dose of 4 mg/m2 to achieve a target plasma concentration of 0.2-0.5 microM. "
01/01/1995 - "Because of dose-limiting mucositis, this dose schedule of trimetrexate is not recommended for further studies in refractory acute leukemia. "
|1.||Leucovorin (Folinic Acid)
|4.||flavone acetic acid
|7.||Tetrahydrofolate Dehydrogenase (Dihydrofolate Reductase)
|1.||Drug Therapy (Chemotherapy)
|3.||Transplantation (Transplant Recipients)